SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,640.48 (-2.78%)
DOW   29,275.45 (-2.18%)
QQQ   269.19 (-3.78%)
AAPL   140.33 (-3.51%)
MSFT   234.39 (-5.02%)
META   133.15 (-4.26%)
GOOGL   98.54 (-2.84%)
AMZN   114.61 (-4.73%)
TSLA   223.85 (-6.00%)
NVDA   121.44 (-7.51%)
NIO   13.70 (-7.24%)
BABA   81.19 (-3.71%)
AMD   59.35 (-12.53%)
T   15.03 (-1.89%)
MU   53.15 (-2.69%)
CGC   2.80 (-25.33%)
F   12.14 (-1.78%)
GE   64.20 (-3.05%)
DIS   96.85 (-3.19%)
AMC   6.46 (-9.27%)
PYPL   90.13 (-4.54%)
PFE   42.22 (-2.02%)
NFLX   228.17 (-4.94%)
S&P 500   3,640.48 (-2.78%)
DOW   29,275.45 (-2.18%)
QQQ   269.19 (-3.78%)
AAPL   140.33 (-3.51%)
MSFT   234.39 (-5.02%)
META   133.15 (-4.26%)
GOOGL   98.54 (-2.84%)
AMZN   114.61 (-4.73%)
TSLA   223.85 (-6.00%)
NVDA   121.44 (-7.51%)
NIO   13.70 (-7.24%)
BABA   81.19 (-3.71%)
AMD   59.35 (-12.53%)
T   15.03 (-1.89%)
MU   53.15 (-2.69%)
CGC   2.80 (-25.33%)
F   12.14 (-1.78%)
GE   64.20 (-3.05%)
DIS   96.85 (-3.19%)
AMC   6.46 (-9.27%)
PYPL   90.13 (-4.54%)
PFE   42.22 (-2.02%)
NFLX   228.17 (-4.94%)
S&P 500   3,640.48 (-2.78%)
DOW   29,275.45 (-2.18%)
QQQ   269.19 (-3.78%)
AAPL   140.33 (-3.51%)
MSFT   234.39 (-5.02%)
META   133.15 (-4.26%)
GOOGL   98.54 (-2.84%)
AMZN   114.61 (-4.73%)
TSLA   223.85 (-6.00%)
NVDA   121.44 (-7.51%)
NIO   13.70 (-7.24%)
BABA   81.19 (-3.71%)
AMD   59.35 (-12.53%)
T   15.03 (-1.89%)
MU   53.15 (-2.69%)
CGC   2.80 (-25.33%)
F   12.14 (-1.78%)
GE   64.20 (-3.05%)
DIS   96.85 (-3.19%)
AMC   6.46 (-9.27%)
PYPL   90.13 (-4.54%)
PFE   42.22 (-2.02%)
NFLX   228.17 (-4.94%)
S&P 500   3,640.48 (-2.78%)
DOW   29,275.45 (-2.18%)
QQQ   269.19 (-3.78%)
AAPL   140.33 (-3.51%)
MSFT   234.39 (-5.02%)
META   133.15 (-4.26%)
GOOGL   98.54 (-2.84%)
AMZN   114.61 (-4.73%)
TSLA   223.85 (-6.00%)
NVDA   121.44 (-7.51%)
NIO   13.70 (-7.24%)
BABA   81.19 (-3.71%)
AMD   59.35 (-12.53%)
T   15.03 (-1.89%)
MU   53.15 (-2.69%)
CGC   2.80 (-25.33%)
F   12.14 (-1.78%)
GE   64.20 (-3.05%)
DIS   96.85 (-3.19%)
AMC   6.46 (-9.27%)
PYPL   90.13 (-4.54%)
PFE   42.22 (-2.02%)
NFLX   228.17 (-4.94%)
NASDAQ:LXRX

Lexicon Pharmaceuticals - LXRX Stock Forecast, Price & News

$2.31
-0.15 (-6.10%)
(As of 10/7/2022 02:27 PM ET)
Add
Compare
Today's Range
$2.30
$2.47
50-Day Range
$2.33
$3.43
52-Week Range
$1.31
$6.33
Volume
24,828 shs
Average Volume
641,273 shs
Market Capitalization
$424.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
541.0% Upside
$15.00 Price Target
Short Interest
Healthy
2.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.42mentions of Lexicon Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$40.43 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.64) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

857th out of 1,075 stocks

Pharmaceutical Preparations Industry

415th out of 537 stocks

LXRX stock logo

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

Lexicon Pharmaceuticals, Inc. (LXRX)
See More Headlines
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Company Calendar

Last Earnings
8/02/2022
Today
10/07/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
87
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+332.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-87,760,000.00
Net Margins
-88,803.67%
Pretax Margin
-88,803.67%

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$0.76 per share

Miscellaneous

Free Float
171,690,000
Market Cap
$424.19 million
Optionable
Optionable
Beta
1.44

Social Links


Key Executives

  • Mr. Lonnel Coats (Age 57)
    CEO & Director
    Comp: $1.14M
  • Mr. Jeffrey L. Wade J.D. (Age 57)
    Pres & CFO
    Comp: $718.14k
  • Mr. Brian T. Crum (Age 49)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $557.49k
  • Dr. Alan J. Main Ph.D. (Age 68)
    Exec. VP of Innovation & Chemical Sciences
    Comp: $574.2k
  • Dr. Craig B. Granowitz M.D. (Age 57)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $450.46k
  • Dr. Robert J. Lefkowitz M.D. (Age 78)
    Consultant & Independent Director
    Comp: $50k
  • Ms. Kristen L. Alexander (Age 54)
    VP of Fin. & Accounting
  • Chas Schultz
    Exec. Director of Corp. Communications & Patient Advocacy
  • Ms. Wendy E. McDermott (Age 51)
    VP of HR
  • Dr. Kenneth B. Kassler-Taub M.D. (Age 66)
    Sr. VP of Regulatory Affairs & Quality Assurance













LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings
or view top-rated stocks.

What is Lexicon Pharmaceuticals' stock price forecast for 2022?

2 Wall Street analysts have issued 12 month price objectives for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $15.00 in the next year. This suggests a possible upside of 541.0% from the stock's current price.
View analysts price targets for LXRX
or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2022?

Lexicon Pharmaceuticals' stock was trading at $3.94 on January 1st, 2022. Since then, LXRX stock has decreased by 40.6% and is now trading at $2.34.
View the best growth stocks for 2022 here
.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our LXRX earnings forecast
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Tuesday, August, 2nd. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company had revenue of $0.04 million for the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 93.58% and a negative net margin of 88,803.67%.

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $2.34.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $429.69 million and generates $300,000.00 in revenue each year. The biopharmaceutical company earns $-87,760,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.